Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population‐based analysis

Abstract

Patients who died of glioblastoma in 2010 had lived with disease significantly longer than patients who died in 2008. The most likely explanation for this change is the approval and use of bevacizumab for progressive glioblastoma, indicating that at a population level, treatment strategies involving bevacizumab prolong survival.